Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro
Clementi et al.
, Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro
, Front. Microbiol., 10 July 2020, doi:10.3389/fmicb.2020.01704 (date from earlier preprint) (In Vitro)
study showing greater inhibition for combined pre and post-exposure treatment for Vero E6 and Caco-2 cells.14 In Vitro studies
support the efficacy of HCQ [Andreani, Clementi, Dang, Delandre, Faísca, Hoffmann, Liu, Ou, Purwati, Sheaff, Wang, Wang (B), Yao, Yuan]
Clementi et al., 31 Mar 2020, peer-reviewed, 10 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
Abstract: ORIGINAL RESEARCH
published: 10 July 2020
Combined Prophylactic and
Therapeutic Use Maximizes
Anti-SARS-CoV-2 Effects in vitro
Nicola Clementi 1,2 , Elena Criscuolo 1 , Roberta Antonia Diotti 1 , Roberto Ferrarese 1 ,
Matteo Castelli 1 , Lorenzo Dagna 3 , Roberto Burioni 1 , Massimo Clementi 1,2 and
Nicasio Mancini 1,2*
Laboratory of Microbiology and Virology, Vita-Salute San Raffaele University, Milan, Italy, 2 Laboratory of Microbiology and
Virology, IRCCS San Raffaele Scientific Institute, Milan, Italy, 3 Unit of Immunology, Rheumatology, Allergy and Rare Diseases
(UnIRAR), IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy
Twincore Center for Experimental and
Clinical Infection Research GmbH,
The University of Texas Medical
Branch at Galveston, United States
This article was submitted to
a section of the journal
Frontiers in Microbiology
Received: 09 April 2020
Accepted: 29 June 2020
Published: 10 July 2020
Clementi N, Criscuolo E, Diotti RA,
Ferrarese R, Castelli M, Dagna L,
Burioni R, Clementi M and Mancini N
(2020) Combined Prophylactic and
Therapeutic Use Maximizes
Effects in vitro.
Front. Microbiol. 11:1704.
While the SARS-CoV-2 pandemic is heavily hitting the world, it is of extreme importance
that significant in vitro observations guide the quick set up of clinical trials. In this study, we
evidence that the anti-SARS-CoV2 activity of a clinically achievable hydroxychloroquine
concentration is maximized only when administered before and after the infection of Vero
E6 and Caco-2 cells. This suggests that only a combined prophylactic and therapeutic
use of hydroxychloroquine may be effective in limiting viral replication in patients.
Keywords: hydroxychloroquine, SARS-CoV-2, COVID-19, prophylaxis, therapy
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.